Kezdőlap・Részvénylista・Viatris Inc

Viatris Inc

Lezárt

SzektorEgészségügy

16.23 1.18

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

15.85

Maximum

16.26

Fő mutatók
By Trading Economics
Bevétel	-295M -119M
Értékesítés	240M 3.8B
Egy részvényre jutó nyereség	0.69
Osztalékhozam	2.92
Profit margin	-3.162
Munkavállalók	30,000
EBITDA	9.4M 653M

Ajánlások
By TipRanks
Ajánlások	Semleges
12 hónapos előrejelzés	+13.28% upside

Osztalékok
By Acuity
Osztalékhozam Szektor átlag	2.92% 2.22%
Következő eredményjelentés	2026. nov. 5.
Következő osztalékfizetési dátum	2026. szept. 16.
Következő korábbi osztalék dátum	2026. aug. 21.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	-1.8B 19B
Előző nyitás	15.05
Előző zárás	16.23

Hangulat hírek alapján

By Acuity

50%

163 / 340 Rangsor szerint Healthcare

Viatris Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 14. 20:06 UTC

Viatris Inc shares are higher today, despite earlier session pullbacks. Broader market sentiment is mixed following a decline in U.S. retail sales.

2026. aug. 13. 20:06 UTC

Viatris Inc shares are lower today, reflecting broader market trends amid rising U.S. jobless claims that exceeded expectations. The stock remains near its one-month range low.

2026. aug. 12. 23:06 UTC

Viatris Inc. shares moved higher in after-market trading, recovering from earlier losses. The stock remains below its 20-day moving average.

2026. aug. 11. 23:41 UTC

Viatris Inc. shares rose in after-market trading, despite earlier fluctuations and broader market concerns about inflationary pressures and oil prices.

2026. aug. 10. 19:42 UTC

Pharmaceuticals sector strength is lifting Viatris Inc during Monday's session, with increased trading volume contributing to the upward movement.

2026. aug. 7. 22:01 UTC

Viatris Inc. shares are higher in after-market trading, supported by a broader equity rally following weaker employment data and reduced interest rate hike concerns.

2026. aug. 6. 23:01 UTC

Viatris Inc shares are higher in after-market hours, recovering from earlier lows. The stock is trading above Thursday's close despite recent declines.

2026. aug. 5. 23:11 UTC

Viatris Inc. shares are trading higher in after-market hours, recovering significantly above the 20-day moving average amid broader market optimism despite no specific news.

2026. aug. 4. 23:06 UTC

Viatris Inc shares are higher in after-market trading, reflecting positive momentum and positioning above the 20-day moving average. No specific news was identified.

2026. aug. 3. 20:06 UTC

Viatris Inc shares are higher today, reflecting broader market gains led by major stocks. The S&P 500 and Nasdaq 100 have also risen.

2026. júl. 31. 21:02 UTC

Viatris Inc shares are lower in after-market hours, continuing a four-session decline amid rising inflation concerns and higher crude oil prices.

2026. júl. 30. 18:56 UTC

Event

Viatris shares are trading lower despite FDA approval of the Gwyn Lo contraceptive patch. Broader economic data may be impacting the stock's performance.

2026. júl. 29. 22:03 UTC

Event

Viatris Inc. shares are lower in after-market hours despite FDA approval of the Gwyn Lo contraceptive patch, amid broader market caution over geopolitical tensions.

2026. júl. 28. 19:36 UTC

Social Media

Viatris shares are higher today, supported by strong sector gains and a significant rise in January 2027 $10 call options activity.

2026. júl. 27. 19:11 UTC

Viatris Inc shares are higher today, breaking a trend of daily gains. No specific news was identified to explain this movement.

2026. júl. 23. 20:06 UTC

Viatris Inc's shares are higher during Thursday's session, continuing an upward trend since Wednesday's close. No specific news was identified to explain the movement.

2026. júl. 22. 23:16 UTC

Viatris Inc shares are higher in after-market hours, recovering from an earlier dip and reflecting strength amid rising crude oil prices.

2026. júl. 21. 18:46 UTC

Viatris Inc shares are higher today, rebounding after an earlier dip amid a broader recovery in U.S. markets and renewed investor optimism.

2026. júl. 20. 19:21 UTC

News

Viatris Inc shares are lower amid negative sentiment in the Pharmaceuticals sector. Analysts cite a price target of $17.81, reflecting concerns over sales declines.

Társak összehasonlítása

Árváltozás

Viatris Inc Előrejelzés

Célár

By TipRanks

13.28% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 18.17 USD 13.28%

Magas 23 USD

Alacsony 12 USD

6 Wall Street elemző 12 hónapos célárain alapulva a(z)Viatris Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Semleges

6 ratings

Vétel

Tartás

Eladás

6 Wall Street elemző célárain alapulva a(z)Viatris Inc termékhez az elmúlt 3 hónapban.

Hangulat

By Acuity

163 / 340 Rangsor szerint Egészségügy

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk Viatris Inc

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.